Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib PK in Hepatic Impairment
NCT02387814Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in breast cancer (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration at 192 hours and Area Under the Concentration Versus Time Curve at 192 hours. Started Mar 2015; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02387814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387814.